Zydus Healthcare launches highly affordable Dapagliflozin tablets in India for the treatment of Type 2 diabetes

▴ zydus-healthcare-launches-highly-affordable-dapagliflozin-tablets-in-india-for-the-treatment-of-type-2-diabetes
Zydus Healthcare Limited announced that it is launching the anti-diabetic Dapagliflozin tablets in India upon its patent expiry under the brand name ‘Dapaglyn’

Zydus Healthcare Limited announced that it is launching the anti-diabetic Dapagliflozin tablets in India upon its patent expiry under the brand name ‘Dapaglyn’. In keeping with its efforts to make therapies accessible and affordable to patients, the drug will be highly economical, priced at 1/3rd the cost than currently available Dapagliflozin brands in India. A once-daily oral treatment indicated as an adjunct to diet and exercise, Dapaglyn aims to improve glycemic control in adults with Type 2 diabetes mellitus.

Dapagliflozin is part of a newer class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. People who have diabetes can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking Dapagliflozin, along with lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking one’s blood sugar may help patients manage their blood sugar levels and improve their health.

With diabetes becoming a major health burden in India which has a patient population of almost 77 million diabetics, it is critical to have therapies that are affordable and accessible to patients from all sections of society. With Dapaglyn, a new generation of anti-diabetic therapy will now be accessible to a larger number of patients, thereby bringing in better compliance and improved disease management.

Tags : #LatestPharmaNewsSep4 #LatestZydusNewsSep4 #TreatmentforType2Diabetes #anti-diabetic #Dapagliflozintablets

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Uncovering the Presence of Microplastics in Human Blood and Their Health EffectsMay 18, 2024
Potential Risks of Meftal: What Consumers and Doctors Should KnowMay 18, 2024
Over-the-Counter Medications in India: A New Era of AccessibilityMay 18, 2024
DCGI Acts Against Overcharging: New Regulations for Blood CentresMay 17, 2024
Cattle as Hosts for Human and Bird Flu Viruses: A Potential Public Health ConcernMay 17, 2024
The Ethics of Live Surgery Broadcasts: NMC Seeks Public OpinionMay 17, 2024
Successful Removal of 3.7 KG Large Abdominal Tumor from 14-Year-Old Somalian Girl at KIMS Cuddles HospitalMay 16, 2024
iLEAD Sets a Precedent by Launching a Graphic Anthology Authored by Multimedia, Animation and Graphics Students May 16, 2024
Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT); Achieves significant advancement in Cancer Treatment to Enhance Quality of LifeMay 16, 2024
IIITH Announces Product Management Summer SchoolMay 16, 2024
Çelebi India's Delhi Cargo Terminal Successfully Handles Airbus H125 Helicopter ShipmentMay 16, 2024
Plant-Based Diets and Prostate Cancer: New UCSF Study Shows Promising ResultsMay 16, 2024
National Medical Commission Approves 112 New Medical CollegesMay 16, 2024
Study Suggests That Chemotherapy Results in Physical Decline for Older Women with Breast CancerMay 16, 2024
Google DeepMind's AlphaFold 3: Revolutionizing Drug Discovery with AIMay 16, 2024
Hester Biosciences Ltd reports Consolidated Revenue growth of 18% at Rs. 79.3 crore, EBITDA up 37% to Rs. 16.4 crore and Net Profit up 12% to Rs. 6.40 crore in Q4FY24May 16, 2024
Akshay Tritiya Parna Mahotsav heldMay 16, 2024
IT Minister Sridhar Babu to grace the 10th National Facilities Managers Summit-2024, to be held in the cityMay 15, 2024
Alarming Study Reveals Cancer-Causing Chemicals in Car InteriorsMay 15, 2024
India's Thalassemia Challenge: The Importance of Early Screening and TreatmentMay 15, 2024